A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).
CompletadoFase 4ClinicalTrials.gov
ID: NCT00156078Tipo: INTERVENTIONALInicio: 1 de ene de 2005Fin estimado: 1 de may de 2007
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
Elegibilidad
Edad mínima: 18 YearsSexo: ALL
Criterios de inclusión
Diagnosis of Type 1 or 2 diabetes mellitus.
Diagnosis of painful DPN for at least 12 months but less than 5 years in duration.
Criterios de exclusión
Neurologic Disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.
Presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain.
Intervenciones
drug
pregabalin
Ubicaciones
Pfizer Investigational Site
Buenos Aires, Argentina
Patrocinadores
PrincipalPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A 14-Week, Double-Blind, Randomized, Placebo-Controlled, ... | EligiMed